Self-Assembled Chambered Cardiac Organoids for Modeling Cardiac Chamber Formation and Cardiotoxicity Assessment

Xinle Zou,Fanwen Wang,Huilin Zheng,Tianci Kong,Duanqing Pei

DOI: https://doi.org/10.1101/2024.07.25.605044

2024-07-25

Abstract:The human heart, crucial for health and longevity, is a primary focus of medical research. Despite advancements in cardiac organoid technology, replicating early cardiac chamber formation stages remains challenging. Here, we develop chambered cardiac organoids (CCOs) by orchestrating cardiac signaling pathways, including the synergistic modulation of FGF and Wnt signaling via the HAND1 transcription factor. These CCOs exhibit stable chambers with self-organized outer myocardial and inner endocardial layers, and express developmental markers such as NKX2.5, TNNT2, and NAPPA, demonstrating physiological functionality including spontaneous contractions and calcium transients. Immunofluorescence and single-cell RNA sequencing confirmed the presence and stability of cardiomyocytes within CCOs. Further validation showed CCOs' involvement in critical processes like endothelial-mesenchymal transition (EndoMT) and valvulogenesis. Ultrastructural and electrophysiological analysis revealed organized myofibrils and atrial-like action potentials. Importantly, CCOs proved effective in assessing cardiotoxicity through observable morphological changes, demonstrating specific cellular responses to established cardiotoxic compounds, thereby highlighting their potential for drug testing and safety evaluations. Our findings offer insights into cardiac chamber formation mechanisms and establish a robust platform for drug testing, disease modeling, and personalized medicine, representing a significant advancement in functional cardiac organoid development for both basic research and translational applications.

Cell Biology

What problem does this paper attempt to address?

The main problem this paper attempts to address is how to construct self-assembling cardiac organoids (CCOs) that can accurately mimic the stage of heart chamber formation. Although current cardiac organoid technologies have made some progress, they still face challenges in replicating early heart chamber formation. Specifically, existing cardiac organoids often lack stable chamber structures, distinct outer myocardial and inner endocardial layers, and the ability to self-organize.

To solve these issues, the research team successfully constructed self-assembling cardiac organoids (CCOs) with stable chamber structures by coordinating cardiac signaling pathways, particularly through the HAND1 transcription factor, which synergistically regulates the FGF and Wnt signaling pathways. These CCOs have the following characteristics:

1. **Stable chamber structure**: CCOs formed stable single chambers in 100% of the organoids, which could persist until day 90.5.
2. **Distinct outer myocardial and inner endocardial layers**: Immunofluorescence analysis and single-cell RNA sequencing confirmed the presence of distinct outer myocardial and inner endocardial layers in the CCOs.
3. **Expression of specific developmental markers**: CCOs expressed markers related to cardiac development, such as NKX2.5, TNNT2, and NAPPA.
4. **Physiological function**: CCOs exhibited physiological functional characteristics such as spontaneous contraction and calcium transients.

Additionally, the study validated the potential of CCOs in assessing drug cardiotoxicity. By observing the morphological changes of CCOs when exposed to known cardiotoxic compounds (such as thalidomide and all-trans retinoic acid), it was confirmed that CCOs can effectively evaluate drug cardiotoxicity, thereby providing a new platform for drug testing and safety evaluation.

In summary, this study not only addresses the shortcomings of existing cardiac organoids in mimicking early heart chamber formation but also provides a powerful tool for cardiac disease modeling, drug testing, and personalized medicine.